|
1
|
Agarwal R and Kaye SB: Ovarian cancer:
strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reed E, Kohn EC, Sarosy G, et al: M
Paclitaxel, cisplatin, and cyclophosphamide in human ovarian
cancer: molecular rationale and early clinical results. Semin
Oncol. 22(3 Suppl 6): 90–96. 1995.PubMed/NCBI
|
|
3
|
Raja FA, Counsell N, Colombo N, et al:
Platinum versus platinum-combination chemotherapy in
platinum-sensitive recurrent ovarian cancer: a meta-analysis using
individual patient data. Ann Oncol. 24(12): 3028–3034. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Einzig AI, Wiernik PH, Sasloff J, Runowicz
CD and Goldberg GL: Phase II study and long-term follow-up of
patients treated with taxol for advanced ovarian adenocarcinoma. J
Clin Oncol. 10:1748–1753. 1992.PubMed/NCBI
|
|
5
|
Tian C, Ambrosone CB, Darcy KM, et al:
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical
outcomes among women with advanced stage ovarian cancer treated
with platinum and taxane-based chemotherapy: a Gynecologic Oncology
Group study. Gynecol Oncol. 124:575–581. 2012. View Article : Google Scholar :
|
|
6
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McGuire WP 3rd: Current status of taxane
and platinum-based chemotherapy in ovarian cancer. J Clin Oncol.
21(Suppl 10): 133–135. 2003. View Article : Google Scholar
|
|
8
|
Ozols RF: Systemic therapy for ovarian
cancer: current status and new treatments. Semin Oncol. 33:3–11.
2006. View Article : Google Scholar
|
|
9
|
Robinson DR, Wu YM and Lin SF: The protein
tyrosine kinase family of the human genome. Oncogene. 19:5548–5557.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohashi K, Mizuno K, Kuma K, Miyata T and
Nakamura T: Cloning of the cDNA for a novel receptor tyrosine
kinase, Sky, predominantly expressed in brain. Oncogene. 9:699–705.
1994.PubMed/NCBI
|
|
11
|
O’Bryan JP, Frye RA, Cogswell PC, et al:
axl, a transforming gene isolated from primary human myeloid
leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell
Biol. 11:5016–5031. 1991.
|
|
12
|
Janssen JW, Schulz AS, Steenvoorden AC, et
al: A novel putative tyrosine kinase receptor with oncogenic
potential. Oncogene. 6:2113–2120. 1991.PubMed/NCBI
|
|
13
|
Rescigno J, Mansukhani A and Basilico C: A
putative receptor tyrosine kinase with unique structural topology.
Oncogene. 6:1909–1913. 1991.PubMed/NCBI
|
|
14
|
Sasaki T, Knyazev PG, Clout NJ, et al:
Structural basis for Gas6-Axl signalling. EMBO J. 25:80–87. 2006.
View Article : Google Scholar
|
|
15
|
Stitt TN, Conn G, Gore M, et al: The
anticoagulation factor protein S and its relative, Gas6, are
ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
Cell. 80:661–670. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hafizi S and Dahlbäck B: Gas6 and protein
S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase
subfamily. FEBS J. 273:5231–5244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zwick E, Bange J and Ullrich A: Receptor
tyrosine kinase signalling as a target for cancer intervention
strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Challier C, Uphoff CC, Janssen JW and
Drexler HG: Differential expression of the ufo/axl oncogene in
human leukemia-lymphoma cell lines. Leukemia. 10:781–787.
1996.PubMed/NCBI
|
|
19
|
Graham DK, Salzberg DB, Kurtzberg J, et
al: Ectopic expression of the proto-oncogene Mer in pediatric
T-cell acute lymphoblastic leukemia. Clin Cancer Res. 12:2662–2669.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De Vos J, Couderc G, Tarte K, et al:
Identifying intercellular signaling genes expressed in malignant
plasma cells by using complementary DNA arrays. Blood. 98:771–780.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meric F, Lee WP, Sahin A, Zhang H, Kung HJ
and Hung MC: Expression profile of tyrosine kinases in breast
cancer. Clin Cancer Res. 8:361–367. 2002.PubMed/NCBI
|
|
22
|
Tavazoie SF, Alarcón C, Oskarsson T, et
al: Endogenous human microRNAs that suppress breast cancer
metastasis. Nature. 451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Craven RJ, Xu LH, Weiner TM, et al:
Receptor tyrosine kinases expressed in metastatic colon cancer. Int
J Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu CW, Li AF, Chi CW, et al: Clinical
significance of AXL kinase family in gastric cancer. Anticancer
Res. 22:1071–1078. 2002.PubMed/NCBI
|
|
25
|
Tsou AP, Wu KM, Tsen TY, et al: Parallel
hybridization analysis of multiple protein kinase genes:
identification of gene expression patterns characteristic of human
hepatocellular carcinoma. Genomics. 50:331–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Györffy B and Lage H: A Web-based data
warehouse on gene expression in human malignant melanoma. J Invest
Dermatol. 127:394–399. 2007. View Article : Google Scholar
|
|
27
|
Macleod K, Mullen P, Sewell J, et al:
Altered ErbB receptor signaling and gene expression in
cisplatin-resistant ovarian cancer. Cancer Res. 65:6789–6800. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005. View Article : Google Scholar
|
|
29
|
Chung BI, Malkowicz SB, Nguyen TB,
Libertino JA and McGarvey TW: Expression of the proto-oncogene Axl
in renal cell carcinoma. DNA Cell Biol. 22:533–540. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Ginkel PR, Gee RL, Shearer RL, et al:
Expression of the receptor tyrosine kinase Axl promotes ocular
melanoma cell survival. Cancer Res. 64:128–134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ozben T: Oxidative stress and apoptosis:
impact on cancer therapy. J Pharm Sci. 96:2181–2196. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lau AT, Wang Y and Chiu JF: Reactive
oxygen species: current knowledge and applications in cancer
research and therapeutic. J Cell Biochem. 104:657–667. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Permuth-Wey J and Sellers TA: Epidemiology
of ovarian cancer. Methods Mol Biol. 472:413–437. 2009.
|
|
34
|
Collado M and Serrano M: Senescence in
tumours: evidence from mice and humans. Nat Rev Cancer. 10:51–57.
2010. View
Article : Google Scholar
|
|
35
|
Gioia R, Leroy C, Drullion C, et al:
Quantitative phosphoproteomics revealed interplay between Syk and
Lyn in the resistance to nilotinib in chronic myeloid leukemia
cells. Blood. 118:2211–2221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dufies M, Jacquel A, Belhacene N, et al:
Mechanisms of AXL overexpression and function in Imatinib-resistant
chronic myeloid leukemia cells. Oncotarget. 2:874–885.
2011.PubMed/NCBI
|
|
37
|
Achuthan S, Santhoshkumar TR, Prabhakar J,
Nair SA and Pillai MR: Drug-induced senescence generates
chemoresistant stemlike cells with low reactive oxygen species. J
Biol Chem. 286:37813–37829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhong Z, Wang Y, Guo H, et al: Protein S
protects neurons from excitotoxic injury by activating the TAM
receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through
its sex hormone-binding globulin-like region. J Neurosci.
30:15521–15534. 2010. View Article : Google Scholar : PubMed/NCBI
|
